Modeling Long-Term Progression-Free Survival in Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone.
Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) significantly improved progression-free survival (PFS) versus VRd in newly diagnosed multiple myeloma (NDMM) in transplant eligible (TE; PERSEUS) and transplant-ineligible (TIE; CEPHEUS) populations. Median PFS with DVRd has not been reached in either stud...